Alan Dunton, M.D.
Alan W. Dunton, M.D., has served as a member of our Board of Directors since 2011. Dr. Dunton has over 25 years of experience as an executive in the pharmaceutical/biotechnology industry. His career has ranged from responsibility for overall leadership of large pharmaceutical research & development organizations to private biotechnology companies focused on prescription (Rx) and over-the-counter (OTC) drug development, as well as devices. Dr. Dunton is the founder and principal of Danerius, LLC, a consulting firm that works with small to mid-size pharmaceutical companies to guide them through drug development programs and regulatory issues, assist them in identifying and evaluating product opportunities, and secure funding or partnering opportunities. He has held several senior positions in major pharmaceutical companies. Most recently, he served as President and Chief Executive Officer of Panacos Pharmaceuticals, Inc., a company focused on treatment resistant HIV therapeutics. Previously, he was the President and CEO of Metaphore Pharmaceuticals, which focused on anti-inflammatory and analgesic products. Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson, including President and Managing Director of The Janssen Research Foundation. He also served as Group Vice President of Global Clinical Research & Development of Janssen, as well as the R.W. Johnson Pharmaceutical Research Institute, also a Johnson & Johnson company. Dr. Dunton has also held positions in clinical research & development at Syntex Corporation, CIBA-GEIGY Corporation and Hoffmann La Roche Inc. Dr. Dunton serves on several Boards of Directors, including EpiCept Corporation, as Non-Executive Chairman, Targacept, Inc., Oragenics, Inc. and Palatin Technologies Inc. He earned his M.D. from New York University School of Medicine and a B.S. in Biochemistry, magna cum laude, from State University School of New York at Buffalo.